ArticleAntimicrobial agents and chemotherapy2015
Testing tuberculosis drug efficacy in a zebrafish high-throughput translational medicine screen.
Article in Antimicrobial agents and chemotherapy, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 64 citations in OpenAlex.
- 3D nanoprinting of embryo microinjection needles with anti-clogging features.Microsystems & nanoengineering · 2025Article
- Identification of a Drug Candidate againstJournal of microbiology and biotechnology · 2025Article
- Diving into drug-screening: zebrafish embryos as an in vivo platform for antimicrobial drug discovery and assessment.FEMS microbiology reviews · 2024Review
- Mycobacterium tuberculosis β-lactamase variant reduces sensitivity to ampicillin/avibactam in a zebrafish-Mycobacterium marinum model of tuberculosis.Scientific reports · 2023Article
- Impact of Drug Administration Routes on the In Vivo Efficacy of the Natural Product Sorangicin a Using aInternational journal of molecular sciences · 2023Article
- The zebrafish embryo as an in vivo model for screening nanoparticle-formulated lipophilic anti-tuberculosis compounds.Disease models & mechanisms · 2022Article
- An anti-tuberculosis compound screen using a zebrafish infection model identifies an aspartyl-tRNA synthetase inhibitor.Disease models & mechanisms · 2021Article
- A Screening of the MMV Pandemic Response Box Reveals Epetraborole as a New Potent Inhibitor againstInternational journal of molecular sciences · 2021Article
- Zebrafish larvae as experimental model to expedite the search for new biomarkers and treatments for neonatal sepsis.Journal of clinical and translational science · 2021Review
- Anti-tuberculosis effect of isoniazid scales accurately from zebrafish to humans.British journal of pharmacology · 2020Article
- Zebrafish Embryo Model for Assessment of Drug Efficacy on Mycobacterial Persisters.Antimicrobial agents and chemotherapy · 2020Article
- Animal Models for the Study of Nucleic Acid Immunity: Novel Tools and New Perspectives.Journal of molecular biology · 2020Review
- Thiostrepton: A Novel Therapeutic Drug Candidate forMolecules (Basel, Switzerland) · 2019Article
- Role of β-glucosidase 2 in aberrant glycosphingolipid metabolism: model of glucocerebrosidase deficiency in zebrafish.Journal of lipid research · 2019Article
- Expression Signatures of Cisplatin- and Trametinib-Treated Early-Stage Medaka Melanomas.G3 (Bethesda, Md.) · 2019Article
- Impact of post-hatching maturation on the pharmacokinetics of paracetamol in zebrafish larvae.Scientific reports · 2019Article
- Nano-Sampling and Reporter Tools to Study Metabolic Regulation in Zebrafish.Frontiers in cell and developmental biology · 2019Article
- Article
- The Zebrafish as a Model Host for Invasive Fungal Infections.Journal of fungi (Basel, Switzerland) · 2018Review
- Model organism data evolving in support of translational medicine.Lab animal · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The translational value of zebrafish high-throughput screens can be improved when more knowledge is available on uptake characteristics of potential drugs. We investigated reference antibiotics and 15 preclinical compounds in a translational zebrafish-rodent screening system for tuberculosis. As a major advance, we have developed a new tool for testing drug uptake in the zebrafish model. This is important, because despite the many applications of assessing drug efficacy in zebrafish research, the current methods for measuring uptake using mass spectrometry do not take into account the possible adherence of drugs to the larval surface. Our approach combines nanoliter sampling from the yolk using a microneedle, followed by mass spectrometric analysis. To date, no single physicochemical property has been identified to accurately predict compound uptake; our method offers a great possibility to monitor how any novel compound behaves within the system. We have correlated the uptake data with high-throughput drug-screening data from Mycobacterium marinum-infected zebrafish larvae. As a result, we present an improved zebrafish larva drug-screening platform which offers new insights into drug efficacy and identifies potential false negatives and drugs that are effective in zebrafish and rodents. We demonstrate that this improved zebrafish drug-screening platform can complement conventional models of in vivo Mycobacterium tuberculosis-infected rodent assays. The detailed comparison of two vertebrate systems, fish and rodent, may give more predictive value for efficacy of drugs in humans.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.